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Background: The present work aimed to evaluate the antimycobacterial activity and cytotoxicity of Microcystis
aeruginosa toxins, the MC-LR variant and purified extract of [D-Leu1] microcystin-LR.
Methods: The antimicrobial activity of M. aeruginosa extract and microcystin was evaluated by resazurin microtiter
assay against Mycobacterium tuberculosis, M. terrae, M. chelonae and M. kansasii. The cytotoxicity assay was
performed by trypan blue exclusion against the HTC cell line.
Results: Antimicrobial activity was observed in the hexanic extract of M. aeruginosa (RST 9501 strain) against M.
tuberculosis, including sensitive and resistant strains with minimal inhibitory concentrations (MIC) between 1.93 μM and
0.06 μM. The high activity of M. aeruginosa hexanic extract could be attributed to the major presence of the toxins MC-LR
and [D-Leu1] MC-LR that showed activity at MIC between 53 and 0.42 μM against tested mycobacterial strains. Even at
the highest concentration tested, no toxicity of M. aeruginosa extracts was identified against HTC cells.
Conclusions: These preliminary results suggest that [D-Leu1] MC-LR is a promising candidate for the development of a
new antimycobacterial agent.
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“Nontuberculous mycobacteria” is a general expression ap-
plied for different species of the genus Mycobacterium that
do not belong to the Mycobacterium tuberculosis complex
[1]. They are also recognized as causative agents of oppor-
tunistic infections in humans that affect mainly patients
with preexisting pulmonary diseases – such as chronic ob-
structive pulmonary disease or tuberculosis (TB) – or those
with impaired systemic immunity [2-4]. The latter group
includes patients with HIV infection, leukemia and under
immunosuppressive therapy [5,6].
For most nontuberculous mycobacterial infections,
treatment is based on drugs that may differ according to
the causal agent, in particular between slow- (e.g. M.
avium, M. kansasii) and fast-growing species (e.g. M.
abscessus, M. fortuitum) [1]. In general, drug therapy is
long, costly, and often associated with toxic side effects.* Correspondence: daniferamos@gmail.com
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unless otherwise stated.In addition, high rates of natural antibiotic resistance are
common among nontuberculous mycobacteria, which
increases the challenges for new drug discovery [1,7].
TB remains a major global health problem reaching
millions of people every year and ranking as the second
leading cause of death among infectious diseases world-
wide [8]. The current treatment available against TB es-
tablishes a multidrug regimen that lasts a minimum of
six months and does not guarantee a complete eradica-
tion of the infection [9].
Furthermore, the increased number of TB cases due to
multidrug resistant and extensively drug resistant strains
(MDR and XDR) and HIV co-infection have pointed out
the urgent need for alternative treatment. In recent
years, research on the development of new anti-TB ther-
apies has focused on novel agents from both synthetic
and natural sources [10]. For thousands of years, plant-
derived drugs have been empirically used in the treat-
ment of numerous human disorders. Many conventional
drugs originate from plant sources, such as aspirin (from
willow bark), digoxin (from foxglove), quinine (fromThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[11].
Marine natural products play an important role in
drug development particularly in anticancer, antibiotic
and antiparasitic therapies. It is well known that
macrocyclic peptides may demonstrate drug-like physi-
cochemical and pharmacokinetic properties such as
good metabolic stability, solubility, lipophilicity and
bioavailability [12]. More than 800 secondary metabo-
lites belonging to several classes of substances have
been isolated and identified, which includes enzyme in-
hibitors; photosynthesis inhibitors; antimicrobial, anti-
mitotic, immunosuppressive and antitumor peptides
[13-15].
Microcystins, more than 65 structural variants are cur-
rently known, are cyclic heptapeptides, composed of seven
amino acids, namely, five non-protein and two protein
amino acids. These two protein amino acids distinguish
microcystins from one another, while the other amino acids
are more or less constant among the variants [16-18].
Structural variations have been identified at all seven
positions of the heptapeptide ring. Microcystin-LR
(MC-LR) (Figure 1) is the most commonly identified
cyanotoxin in environmental samples, which presents a
leucine (L) and an arginine (R) respectively in X and Y
positions of the cyclic heptapeptide [19,20]. The com-
bined presence of the two L-amino acids is used in the
nomenclature of the variants while the position 1, which
contains D-Ala, is relatively conserved [21].
Another variant of microcystin is [D-Leu1] MC-LR,
which contains D-Leu in position 1. This toxin was de-
tected in cells of Microcystis aeruginosa (RST 9501
strain) isolated from Patos Lagoon (southern Brazil).
This major waterbody has a history of extensive nuis-
ance blooms and scums of hepatotoxic Microcystis [22].
The present study evaluated the antimycobacterial ac-
tivity and cytotoxicity of Microcystis aeruginosa toxins,
the variant MC-LR and purified extract of [D-Leu1]
microcystin-LR against Mycobacterium tuberculosis, M.
chelonae, M. terrae and M. kansasii.Figure 1 General structure of microcystins (LR) with leucine (L) in the
4 and the structural differences in the position 1 of MC-LR (left) and [Methods
Microcystis culture conditions
Microcystis RST 9501 (UPC Culture Collection, Federal
University of Rio Grande) isolated from the estuary of
Patos Lagoon is the [D-Leu1] MC-LR producing variant
and was grown in BG-11 medium with nitrate as previ-
ously described [23,24].
Preparation of microcystis aeruginosa extracts
The extract was prepared using lyophilized cells of
Microcystis aeruginosa according to the protocol de-
scribed by Beattie et al. [24]. Briefly, the cells were dis-
solved in absolute methanol (Sigma, USA), sonicated
three times and centrifuged (10,000 × g) at 4°C, for ten
minutes. Extracts were evaporated at 40°C and then
redissolved in ultrapure water (Direct Q3, Millipore,
USA). The other extract preparations, presented in
Table 1, replaced methanol with hexane, chloroform or
water. Finally, samples were centrifuged and the super-
natant was collected and stored at-20°C. Microcystin
content was determined using a commercial enzyme-
linked immunosorbent assay (ELISA) with polyclonal
antibodies (EnviroLogix Inc., USA). Different concen-
trations of microcystin were prepared after appropriate
dilutions with phosphate buffered saline (PBS – Ca+2
and Mg+2 free). Characterization of microcystins produced
by the strain RST 9501 was previously reported by Mat-
thiensen et al. [17,25]. For the extraction of microcystin
from cells of the strain RST 9501, the toxin [D-Leu1]
microcystin-LR was purified from cell extracts, following
Lawton et al. [26]. The chemical compound microcystin-
LR was purchased from Sigma (USA).
Finally, both toxins were resuspended in water and
then analyzed by high performance liquid chromatog-
raphy (HPLC – Shimadzu SCL-10Avp, Japan) to deter-
mine the concentration of microcystins prior to tests.
Microcystin analysis
Analysis of microcystin obtained from Microcystis RST
9501 was performed using the HPLC equipment Shimadzuamino acid position 2 and arginine (R) in the amino acid position
D-Leu1] MC-LR (right).
Table 1 Minimum inhibitory concentration (MIC) of





M. aeruginosa (aqueous) R >1.93 R >1.93 R >1.93
M. aeruginosa (hexanic) S ≤0.06 S ≤0.60 S 0.12
M. aeruginosa (chloroformic) R >1.93 R >1.93 R >1.93
M. aeruginosa (methanolic) S 1.93 S 0.96 S 0.96
R: resistant, S: sensitive, H37Rv: sensitive strain, RMPr: rifampicin-resistant strain,
INHr: isoniazid-resistant strain. Extract with MIC > 1.93 μM were
considered inactive.
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C18 Luna (4.6 × 250 mm, 5 μm particle size; Phenomenex,
USA) reversed-phase column at 40°C with UV detection at
238 nm. The mobile phase was Milli-Q water/CH3CN (J.
T. Baker, USA), both containing 0.05 % (v/v) trifluoroacetic
acid (Merck, Germany), initially at 65:35 and using a linear
gradient over 20 minutes of 100 % CH3CN at 1 mL.min
-1.
Isolates and mycobacterium spp. preparation
The antimicrobial activity of Microcystis aeruginosa extract
and microcystin were evaluated against Mycobacterium tu-
berculosis H37Rv (ATCC 27294) pan-susceptible strain and
against two clinical isolate mono-resistant to isoniazid and
rifampicin with katG S315T and rpoB S531L respectively.
Furthermore, M. aeruginosa extract, [D-Leu1] MC-LR, and
microcystin-LR (Sigma, USA) toxins were tested against
the nontuberculous mycobacteria: M. terrae (ATCC15755),
M. chelonae (ATCC 946) and M. kansasii (ATCC12478).
The bacterial suspensions obtained of culture in Ogawa
Kudoh medium for about 14 days were prepared in sterile
water containing pearls of glass of 3 mm. The suspension
was homogenized by vortex agitation and the turbidity was
adjusted in agreement with tube one of the scale of McFar-
land (3.2 × 107 cfu/mL). The inoculum was prepared dilut-
ing the bacterial suspension in the proportion of 1:25 in
medium 7H9 broth [4.7 g of Middlebrook 7H9 broth base
(BD Difco, USA) 2 mL of glycerol (Vetec, Brazil) in 900 mL
of water] enriched with 10 % oleic acid-albumin-dextrose-
catalase (OADC – BBL, Media Additives, USA) [27].
Evaluation of antimycobacterial activity
The method used for the determination of the antimyco-
bacterial activity was the resazurin microtiter assay [28].
In brief, the assay is accomplished on microplates (96
wells) using resazurin as indicator of cellular viability.
Medium 7H9 enriched with 10 % OADC was employed.
The extracts and pure microcystin were weighed, dis-
solved in DMSO and the determination of minimal in-
hibitory concentration (MIC) was carried out starting
from 53 to 0.06 μM in serial dilutions of 1:2.Cytotoxicity assay
The HTC cell line was obtained from the Cell Bank of Rio
de Janeiro, Brazil. HTC cells were grown in RPMI 1640
medium (Gibco, USA) supplemented with sodium bicar-
bonate (0.2 g/L) (Vetec, Brazil), L-glutamine (0.3 g/L)
(Vetec, Brazil), Hepes (25 mM) (Acros, USA) and b-
mercaptoethanol (5 × 10–5 M) (Sigma, Germany), with
10 % fetal bovine serum (Gibco, Brazil), 1 % of antibiotic
and antimycotic (penicillin – 100 U/mL, streptomycin-
100 mg/mL and amphotericin B - 0.25 mg/mL), in dispos-
able plastic flasks, at 37°C.
The cytotoxicity assay was performed by trypan blue
exclusion after 24 hours of incubation with microcystins.
Three independent experiments were carried out using
triplicates in each experiment. Data are expressed as
mean + standard error and analyzed using ANOVA
followed by Tukey’s multiple range test. Significance
level was fixed in 0.05.
Results
M. aeruginosa RST 9501 extracts were evaluated against
M. tuberculosis pan-susceptible (H37Rv), rifampicin-
(RIFr) and isoniazid-resistant strains (INHr). The MIC
for these four extracts ranged from 1.93 μM to 0.06 μM.
The aqueous and chloroformic extracts did not present
antimycobacterial activity within these concentrations.
The methanolic extract had a MIC of 1.93 μM against
H37Rv and of 0.96 μM against the tested resistant
strains. The hexanic extract showed the highest activity,
with a MIC of 0.12 μM against INHr, ≤ 0.60 μM against
RIFr and ≤ 0.06 μM against H37Rv (Table 1). This high
activity of the hexanic extract could be attributed to the
possible greater concentration of lipophilic compounds.
Therefore, the molecules of microcystins (MC-LR and
[D-Leu1] MC-LR) were evaluated against M. tuberculosis
H37Rv, RIFr and INHr strains.
The cyanotoxin MC-LR did not present any inhibitory
activity on the three strains at the concentration of
53 μM. On the other hand, [D-Leu1] MC-LR was active
with a similar MIC (13.2 μM) for susceptible and resist-
ant M. tuberculosis strains (Table 2). Therefore, the iso-
lated cyanotoxin showed a MIC up to 220 times higher
than that of the hexanic extract.
The two microcystins were evaluated against three
nontuberculous mycobacteria showing high activity for
all species tested. M. terrae was the most resistant to
nontuberculous mycobacteria, it showed antimycobac-
terial activity against the two tested toxins with MIC of
6.74 μM and 1.08 μM for [D-Leu1] MC-LR and MC-LR,
respectively (Table 3).
A further comparison between both toxins effects sug-
gested that microcystin MC-LR showed lower activity than
[D-Leu1] MC-LR against M. chelonae and M. kansasii, with
a minimum inhibitory concentration of 2.15 μM for the
Table 2 Minimum inhibitory concentration (MIC) of the
microcystin variant [D-Leu1] MC-LR from extracts of M.
aeruginosa RST 9501 and MC-LR (commercially available)
against M. tuberculosis strains







[D-Leu1] MC-LR S 13.2 S 13.2 S 26.5
MC-LR R >53 R >53 R >53
[D-Leu1] MC-LR: microcystin isolated from the extract of Microcystis RST 9501;
MC-LR: commercially obtained; R: resistant; S: sensitive; H37Rv: sensitive strain;
INHr: isoniazid-resistant strain; RMPr: rifampicin-resistant strain. Extracts with
MIC > 53 μM were considered inactive.
Figure 2 Number of HTC viable cell by trypan blue exclusion test
24 hours after exposure to different concentrations of Microcystis
aeruginosa strain 9501 (578.15 to 93.36 μM) which produces
[D-Leu1] MC-LR. Data are expressed as mean + standard error.
*Indicates significant difference from the control (p < 0.05).
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hibitory concentration of 0.84 μM and 0.42 μM for M. che-
lonae and M. kansasii, respectively.
Exposure of HTC cells to Microcystis aeruginosa strain
9501 which produces [D-Leu1] MC-LR induces a decrease
in viable cell number, as determined by trypan blue exclu-
sion, in a concentration dependent manner, 24 hours after
exposure (Figure 2). There were no differences in the num-
ber of viable cells (p > 0.05) between control and treated
cells in the lowest concentration (96.36 μM). However,
from the concentration of 192.71 μM on, there was signifi-
cant difference (p < 0.05) in the number of viable cells,
which indicates cytotoxic effect. Note that at the highest
concentration (578.15 μM) no viable cell was found.
Discussion
In recent years, there has been a growing interest in the
study of natural peptide molecules, whose mode of ac-
tion promises both low susceptibility to multidrug resist-
ance mechanisms and high activity against a vast range
of microorganisms [29,30]. The application of peptides
for drug discovery is merited because of their ease of
synthesis, large structural diversity and commonly high
potency [31].
The present study identified in extracts from M. aeru-
ginosa RST 9501 active compounds with antimycobac-
terial activity against M. tuberculosis growth, including
sensitive and resistant strains. Several metabolites pro-
duced by cyanobacteria have been identified in the lit-
erature. There is a special interest, because these
secondary metabolites are not only disease causingTable 3 Minimum inhibitory concentration (MIC) of the micro






[D-Leu1] MC-LR S 6.74 S
MC-LR S 1.08 S
[D-Leu1] MC-LR: Microcystin isolated of extract of the Microcystis RST 9501 strain, Magents but also bioactive molecules applied to further
studies [19,32-34]. Some works have identified a range
of cyanobacteria compounds isolated from toxic blooms
of Microcystis, Anabaena and Nostoc known to produce
a diverse array of bioactive compounds exhibiting a
broad spectrum of activity, including anticancer, anti-
viral, antibacterial, antifungal and anti-inflammatory ac-
tivity, besides cytotoxic activities [19,32,34,35].
In this study, four M. aeruginosa extracts were tested,
the methanolic extract was more active against resistant
strains (RIFr and INHr) than sensitive M. tuberculosis
strains. Microcystins are a group of chemically related
cyclic peptides [13] and most commonly studied group
of cyanotoxins,. Therefore, in order to identify the pos-
sible active compounds derived from the hexane extrac-
tion that was more active among the extracts from M.
aeruginosa cells evaluated, the two known cyanotoxins
([D-Leu1] MC-LR and MC-LR) were evaluated against
M. tuberuculosis and three nontuberculous mycobacteria
species.
Between the two variants derived from the same
cyanobacterial toxin, just [D-Leu1] MC-LR showed anti-
microbial activity against three different strains of M.cystin variant from extract of the M. aeruginosa RS9501
rains
M.chelonae (μM) M.kansasii (μM)
0.84 S 0.42
2.15 S 2.15
C-LR: obtained commercially, R: resistant, S: sensible.
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than that of the methanolic and hexane extracts. According
to Pauli et al. [36], the differences between the extract and
pure cyanotoxin activity can be attributable to the MIC of
the crude extract, which may not be a reliable antimycobac-
terial activity indicator, since it, the activity may be to an-
tagonist between the substances, or otherwise, synergism
between them, that decreasing or increasing effects on the
MIC. Moreover, an extract with high activity (lower MIC)
could have several compounds with moderate antimyco-
bacterial activity; becoming it the most active extract with a
pure and isolated substance.
The activity of [D-Leu1] MC-LR was unchanged
against strains of M. tuberculosis resistant to rifampicin
and isoniazid compared to pan-susceptible strains. This
is an important finding since the resistance to isoniazid
and rifampicin comprise a major drawback of tubercu-
losis control programs.
Interestingly, the small antimicrobial activity of the two
studied microcystins variants observed against different
strains of M. tuberculosis was not observed for nontubercu-
lous mycobacteria. MC-LR was less active than [D-Leu1]
MC-LR against M. chelonae and M. kansasii. A few studies
have shown that drug susceptibility of nontuberculous
mycobacteria are distinct from that observed inM. tubercu-
losis because, in general, the resistance of nontuberculous
mycobacteria is related to cell wall permeability and efflux
pumps, specially in the presence of a specific mutation
[37]. In this study, however, M. terrae was less susceptible
against cyanotoxins. In addition, the MIC against M. tuber-
culosis strains was higher than that used against all nontu-
berculous mycobacteria.
The activity of these molecules against M. chelonae is
significant, since it indicates that the low permeability
limits the activity of this kind of hydrophilic molecules,
which impairs treatment [38]. Regarding the mechanism
of action proposed for microcystins is the inhibiting
serine/threonine phosphatases 1 and 2A, which leads to
protein phosphorylation and the consequence is cyto-
skeletal damage, liver necrosis and hemorrhage in the
liver which is directly related to their cytotoxicity and
tumor promoting activity [39]. However, there is only a
few data on tissue concentrations of microcystins in ex-
posed humans or animals, which were obtained after ex-
posure to high toxic doses of microcystins [40].
In our study, a single difference in the chemical consti-
tution of the heptapeptide was significantly important in
increasing the antimycobacterial activity. In addition,
considering that leucine is a hydrophobic amino acid,
this characteristic may interfere in the activity of the
peptide that was enhanced by presence.
According to Mandal et al. [41], variations of amino
acid residues in peptides have received considerable at-
tention since they alter the activity against pathogenicmicroorganisms, which has a significant impact on anti-
bacterial activity [41]. A study showed a difference in
their activity against M. tuberculosis and Mycobacterium
avium-intracellulare by the change of only one amino
acid residue in their peptide moiety [42].
Peptides may adopt secondary structures, which are
responsible for their receptor affinity and biological ac-
tivity. The rational design can be sufficient to endow
antibacterial efficacy and to circumvent drawback effects
in this potential therapeutic agent [30,31].
According to Votto et al. [43] and considering that
microcystins may provoke oxidative stress, the difference in
sensitivity of MDR and non-MDR cells can be associated
with dissimilar antioxidant defenses. In this context, the
higher catalase activity observed in the same work may help
to explain, at least partially, the resistance of MDR cells to
microcystin exposure. This MDR cell line with higher cata-
lase activity also showed lower DNA damage than its par-
ental cell line, suggesting the involvement of reactive
oxygen species (ROS) in the toxicity exerted by this cyano-
toxin. Therefore, the significant increase in ROS production
observed in non-MDR cells, in contrast with MDR cells
when both cell lines were exposed to microcystins, suggest
that MDR cells, at least in part, were more resistant to
microcystins due to a higher antioxidant competence.
These authors also present other factors which may have
contributed for the resistance to microcystin in MDR cells
[43].
The choice of the cell line used in this study was sup-
ported by the fact that it is in the liver that microcystins
are metabolized. The results show a significant sensitiv-
ity of tumoral liver cells to this substance in only
24 hours of exposure.
Conclusions
In the present study, the antimicrobial activity of the
hexanic extract from M. aeruginosa RST 9501 against
M. tuberculosis – including sensitive and resistance
strains, and nontuberculous mycobacteria – was ob-
served and possibly associated with the presence of cya-
notoxins. When the activity of these toxins was assessed,
the variant [D-Leu1] MC-LR was the most active against
tested mycobacterial strains. Moreover, was not identi-
fied cytotoxic activity at concentrations whose anti-
microbial activity. Also, was not identified cytotoxic
activity at concentrations which antimicrobial activity
was observed. These results showed the importance of
detailed studies on the activity of extracts and toxins de-
rived from M. aeruginosa strains as promising bioactive
molecules in the treatment of mycobacterial diseases.
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